e-Therapeutics PLC (LSE:ETX) - Share price - Overview

Stock Report

e-Therapeutics PLC ETX

Last Price
GBX10.00

Day Change
0.00|0.00%

As of 19/01/2018
17:08:18 GMT | GBX
Minimum 15 Minutes Delay.

Last Close10.00p
Day Range10.00 - 10.00
Mkt Cap26.85Mil
52-Wk Range6.00 - 13.25
Yield %0.00
ISINGB00B2823H99
Volume30,730
P/E-3.02
P/SInfinity
P/CF-2.89

Share Price

Total Returns 19/01/2018

 Chg (%)  
More ...
e-Therapeutics PLC8.11 
FTSE 100 TR GBP2.61
 
Financials
201520162017
More ...
Income Statement
Turnover0.000.000.00
Operating Profit-10.18-11.56-16.33
Net Profit-7.78-8.82-13.13
Reported EPS-2.94-3.34-4.91
Balance Sheet
Current Assets37.4228.7817.72
Non Current Assets0.730.800.21
Total Assets38.1629.5917.93
Current Liabilities1.131.161.95
Total Liabilities1.131.161.95
Total Equity37.0228.4315.98
Cash Flow
Operating Cash Flow-10.94-10.93-11.87
Net Change in Cash-5.084.52-1.87
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2018-7.26-2.15--4.65---
2019-6.57-1.95--5.12---

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
08/01/2018PurchaseProfessor Trevor Jones9.2559,4605,500.00
15/12/2017PurchaseProfessor Trevor Jones8.9050,0004,450.00
15/12/2017PurchaseMr. Iain Ross8.90200,00017,800.00
15/12/2017PurchaseMs. Christine Soden8.90120,00010,680.00

Company Profile

e-Therapeutics PLC is a drug discovery company. The company's discovery platform is based on the network of pharmacology and chemical biology. e-Therapeutics operates in a single business segment of drug discovery and development.

Sector

Biotechnology

Market Position

1295 of 1835 Companies

Index

FTSE AIM All Share

Outlook

(26/09/2017) no outlook statement

Next Event 31/01/2018

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-5.1014.0316.43
Div Yld (E)0.004.084.04
PEG (E)0.00-0.471.05
ROCE-75.33178.6617.22
Op Mrgn0.00-7.561.32
EPS Grwth0.005.8512.68
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Iain Ross
Chief Executive OfficerDr. Ray Barlow
Finance Director & Interim COOMr. Steve Medlicott
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.